Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 21Recurrence 8Lymphoma, Large B-Cell, Diffuse 7Leukemia, Myeloid, Acute 4Sarcoma 3Endometrial Neoplasms 3Primary Myelofibrosis 2Neurofibrosarcoma 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell 2Glioblastoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Vascular Neoplasms 1Uterine Neoplasms 1Uterine Diseases 1Triple Negative Breast Neoplasms 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Cancer × selinexor × 1 year × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡